|
gptkbp:instance_of
|
gptkb:chemical_compound
|
|
gptkbp:activities
|
inhibition of IL-23 signaling
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:United_States
gptkb:Native_American_tribe
gptkb:Alder_Bio_Pharmaceuticals
Phase 1
Phase 2
Phase 3
|
|
gptkbp:collaborations
|
gptkb:healthcare_organization
gptkb:Johns_Hopkins_University
gptkb:Stanford_University
gptkb:University_of_Washington
gptkb:Cleveland_Clinic
|
|
gptkbp:developed_by
|
gptkb:Alder_Bio_Pharmaceuticals
|
|
gptkbp:discovered_by
|
rational drug design
|
|
gptkbp:field_of_study
|
gptkb:Company
pharmaceutical development
immunology
|
|
gptkbp:form
|
injection
|
|
gptkbp:frequency
|
once every 4 weeks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ALX-0703
|
|
gptkbp:indication
|
gptkb:ankylosing_spondylitis
gptkb:psoriatic_arthritis
atopic dermatitis
hidradenitis suppurativa
|
|
gptkbp:ingredients
|
C_20 H_22 N_4 O_5 S
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_similar_to
|
gptkb:tildrakizumab
gptkb:ustekinumab
gptkb:guselkumab
|
|
gptkbp:is_used_for
|
autoimmune diseases
|
|
gptkbp:manager
|
subcutaneous
|
|
gptkbp:market
|
not approved
|
|
gptkbp:related_to
|
gptkb:Crohn's_disease
gptkb:ulcerative_colitis
Psoriasis
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
injection site reactions
|
|
gptkbp:status
|
ongoing
investigational
|
|
gptkbp:target_audience
|
gptkb:Person
adults
|
|
gptkbp:targets
|
gptkb:IL-23
|
|
gptkbp:type
|
gptkb:monoclonal_antibody
|
|
gptkbp:type_of
|
123456-78-9
|
|
gptkbp:weight
|
402.47 g/mol
|
|
gptkbp:year_created
|
gptkb:2015
|
|
gptkbp:bfsParent
|
gptkb:Ablynx
|
|
gptkbp:bfsLayer
|
4
|